Celera Diagnostics Submits Product for FDA Approval | GenomeWeb

NEW YORK, July 31 – Celera Diagnostics has sought marketing approval from the FDA for its HIV drug resistance system, the company announced Tuesday.

The premarket notification submission was made for Celera Diagnostics’ ViroSeq HIV-1 Genotyping System, an in vitro  method for detecting drug resistance in the HIV-1 virus genome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.